Gene:
ARID1A
AT rich interactive domain 1A (SWI-like)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  B120; BAF250; BAF250a; C10rf4; P270
PharmGKB Accession Id: PA35960

Details

Cytogenetic Location: chr1 : p35.3 - p36.11
GP mRNA Boundary: chr1 : 27022522 - 27108601
GP Gene Boundary: chr1 : 27012522 - 27111601
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. chromatin remodeling by hswi/snf atp-dependent complexes - (BioCarta via Pathway Interaction Database)
  2. control of gene expression by vitamin d receptor - (BioCarta via Pathway Interaction Database)
  3. the information processing pathway at the ifn beta enhancer - (BioCarta via Pathway Interaction Database)

Publications related to ARID1A: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (New York, N.Y.). 2008. Varambally Sooryanarayana, et al. PubMed

LinkOuts

Entrez Gene:
8289
OMIM:
603024
UCSC Genome Browser:
NM_006015
RefSeq RNA:
NM_006015
NM_139135
RefSeq Protein:
NP_006006
NP_624361
MutDB:
ARID1A
ALFRED:
LO061205O
HuGE:
ARID1A
ModBase:
Q9HBJ5
HumanCyc Gene:
HS04169
HGNC:
11110

Common Searches